Targeting opioid receptors: A new treatment for brain disorders.
Rahman
Shafiqur
S
Department of Pharmaceutical Sciences, South Dakota State University, Brookings, USA. shafiqur.rahman@sdstate.edu
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D006801:Humans; D008032:Limbic System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011921:Rats, Inbred WKY / Q000502:physiology* / Q000523:psychology; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000928:Antidepressive Agents; D009292:Narcotic Antagonists; D017473:Receptors, Opioid, kappa; C051844:norbinaltorphimine; D009271:Naltrexone